US pushes Germany on drug pricing while FDA faces turmoil and biotech trials advance, says Pharmalittle roundup

The newsletter notes that U.S. lawmakers are intensifying pressure on Germany to lower the prices of pharmaceuticals, a move that could reshape cross-border pricing negotiations.

At the same time, the Food and Drug Administration is experiencing internal disruptions, described as upheaval, which may affect its regulatory timeline and oversight.

Biotech companies continue to push forward with clinical trials, with several studies highlighted as progressing despite the broader regulatory turbulence.

Overall, the Pharmalittle roundup bundles these developments with other industry news, reflecting a week of policy and operational challenges for the sector.